EyePoint Pharmaceuticals, Inc. announced its 2022 clinical pipeline plans. 2022 Clinical Plans: Updated eight-month data from the Phase 1 DAVIO study of EYP-1901 for wet AMD has 7 of 17 patients (41%) out to eight months rescue free and continued positive safety profile. Detailed data will be presented on February 12, 2022 at the Angiogenesis 2022 virtual meeting.

Initiate a randomized, controlled Phase 2 study of EYP-1901 for wet AMD in the third quarter of 2022. The twelve-month wet AMD Phase 2 trial is expected to enroll 144 patients, randomly assigned to one of two doses of EYP-1901 (approximately 2mg or 3mg) or aflibercept control with efficacy endpoints of change in BCVA (best corrected visual acuity), change in CST (central subfield thickness as measured by OCT), time to rescue and safety. Initiate a randomized, controlled Phase 2 study of EYP-1901 in diabetic retinopathy (DR) in the second half of 2022.

Continue investment in clinical and R&D organization to support pipeline expansion and growth.